Lipocalin-13 Antibody

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

LCN-13 (Lipocalin 13; also Odorant-binding protein 2a) is a secreted, 26-28 kDa member of the LCN family, calycin superfamily of molecules. Its name is derived from Greek, and denotes the fact that lipocalins are known to be "fat-wrapping", or fat binding proteins that interact with small lipophilic molecules within a central cavity. LCN-13 is expressed by hepatocytes and smooth muscle cells. It is known to have antidiabetogenic effects, including the suppression of hepatic glucose production, the uptake of circulating glucose by adipocytes, and the induction of fatty acid oxidation by liver, possibly by stimulating CPT1 alpha production. Mouse LCN‑13 is synthesized as a 176 amino acid (aa) precursor that contains a 19 aa signal sequence and a 157 aa mature region. Although no splice forms have been reported for LCN-13 to date, a smaller, presumably proteolytically processed 23-26 kDa isoform has been noted on SDS-PAGE. Mature mouse LCN-13 shares 69% and 39% aa sequence identity with rat LCN-13 and human odorant-binding protein 2b, respectively.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: Western Blot.

Showing Publications 1 - 2 of 2.

Publications using AF7974	Applications	Species
Lea Bühler, Adriano Maida, Elena Sophie Vogl, Anastasia Georgiadi, Andrea Takacs, Oliver Kluth et al. Lipocalin 13 enhances insulin secretion but is dispensable for systemic metabolic control Life Science Alliance 2021-04-01 [PMID: 33536239]
Control of diabetic hyperglycaemia and insulin resistance through TSC22D4 Nat Commun, 2016-11-09;7(0):13267. 2016-11-09 [PMID: 27827363] (Western Blot, Mouse)	Western Blot	Mouse

Array AF7974

• Lipocalin-13 Antibody
• Lipocalin-13 Proteins and Enzyme